Last reviewed · How we verify
NCT05781581
A Retrospective Cohort Study for Main Postoperative Complications After SARS-CoV-2 Infection
trial testing no intervention in Intestines Cancer in 50,000 participants. Status unknown.
31 August 2023
Quick facts
| Lead sponsor | RenJi Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 50,000 |
| Start date | 19 March 2023 |
| Primary completion | 31 August 2023 |
| Estimated completion | 31 December 2024 |
Drugs / interventions tested
- no intervention
Conditions studied
- Intestines Cancer — all drugs for Intestines Cancer →
- Pulmonary Cancer — all drugs for Pulmonary Cancer →
- Liver Cancer — all drugs for Liver Cancer →
- Trauma — all drugs for Trauma →
Sponsor
RenJi Hospital
Who can join
18 and older, any sex, with Intestines Cancer or Pulmonary Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To explore the relationship between SARS-CoV-2 infection in different time before operation and postoperative main complications (mortality, main pulmonary and cardiovascular complications) 30 days after operation; To determine the best timing of surgery after SARS-CoV-2 infection.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05781581
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of no intervention
Trials testing the same drug.
- NCT07480057 — Assessment of Changes in Bone Mineral Metabolism After Liver Transplantation by Bone Mineral Densitometry · recruiting
- NCT07253506 — Turkish Adaptation, Validity, and Reliability Study of the Patient Experience With Treatment and Self-Management Scale i · not yet recruiting
- NCT07253519 — The Relationship Between Mood and Insomnia Severity and Caregiver Burden in Caregivers of Stroke · not yet recruiting
- NCT07194096 — Stress Hyperglycemia Ratio and Postoperative Delirium · not yet recruiting
- NCT07240337 — Botulinum Toxin Applications in Hemiplegic Patients · recruiting
Other RenJi Hospital trials
Trials by the same sponsor.
- NCT07584733 — Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper · Phase 2 · not yet recruiting
- NCT07537725 — EEG-TMS for Postoperative Delirium After Cardiac Surgery · NA · not yet recruiting
- NCT07527936 — A Study of BEN301 Injection in theTreatment of Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
- NCT07343076 — Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE · NA · not yet recruiting
- NCT07449793 — Biochemical Response and Clinical Outcomes in Patients With PBC · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05781581 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by RenJi Hospital
- Last refreshed: 23 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05781581.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing